Agoracom Blog

Supreme Pharmaceuticals Inc. Announces Brayden R. Sutton as Executive V.P

Posted by AGORACOM-JC at 11:16 AM on Thursday, August 28th, 2014

VANCOUVER, BRITISH COLUMBIA–(Aug. 28, 2014) – Supreme Pharmaceuticals Inc. (“Supreme” or the “Company”) (OTCBB:SPRWF)(CSE:SL) is pleased to announce Brayden R. Sutton as Executive Vice President.

Mr. Sutton will be responsible to oversee operations, assisting in the overall design and completion of the facilities, marketing, financing and business development.

Mr. Sutton has been involved on the research and analysis side of cannabis and cannabis related businesses for over 10 years. Brayden has a thorough understanding of the science of cannabis, the patients who use it, and close ties to the physician community.

He brings over 12 years of successful experience in the capital markets as an investor and financier since 2002 as well as extensive management and operational experience overseeing large-scale projects. He is also President and CEO of CannabisHealth.com as well as having served as the only Canadian Analyst for 420Investor.com.

David Stadnyk, President and CEO stated:

“We are very pleased Brayden is joining the Company as he will be a great addition to our management team with his thorough knowledge of the industry and deep understanding of our business”.

FORWARD LOOKING INFORMATION

This news release contains forward-looking statements. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. This news release includes forward-looking statements with respect to the up grading of the facility, the timing on completion of the MMPR License conditions and the start of production. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this news release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com and such factors as the Company failing to finish the upgrading of the facility and put the same into production in accordance within the terms of the MMPR license. This news release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbour provisions of the Private Securities Litigation Reform Act of 1995.

Supreme Pharmaceuticals Inc.
Investor Relations
430 – 580 Hornby Street, Vancouver BC, V6C 3B6
604.674.2191
[email protected]
www.supremepharmaceuticals.com

Start your small cap medical marijuana research in the AGORACOM Small Cap 
Medical Marijuana Stocks Gateway: 
http://agoracom.com/portal/Small%20Cap%20Medical%20Marijuana%20Stocks

Tags: , , ,

Comments are closed.